19 completed, 13 recruiting, 11 active not recruiting, 9 unknown. 33 Phase 2, 20 Not applicable, 6 Phase 1, 6 Phase 3, 1 Early Phase 1.
Follow Cystectomy: new trials by email Literature Review of Cystectomy trials Research Report on Cystectomy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Post-surgical Delirium in Patients Undergoing Radical Cystectomy. Radical cystectomy. - Delirium, Radical Cystectomy | Not yet recruiting | University of Alexandria | 100 | 2028-11-25 | 2025-04-03 | |
| Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial Nadofaragene Firadenovec, Durvalumab, Gemcitabine - Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8 | Phase 2 | Not yet recruiting | University of Washington | 33 | 2026-12-01 | 2026-10-26 |
| Bladder Preservation or Cystectomy for MIBC Gemzar, Cisplatin, Adrucil - Muscle-Invasive Bladder Carcinoma, Bladder Cancer | Early Phase 1 | Active not recruiting | Dana-Farber Cancer Institute | 20 | 2026-09-02 | 2026-09-15 |
| Partial Cystectomy & Extended Pelvic Lymph Node Dissection With SOC Perioperative Systemic Therapy Neoadjuvant Chemotherapy, Partial cystectomy with Extended pelvic lymph node dissection, Adjuvant systemic therapy - Malignant Neoplasm of Bladder, Muscle Invasive Bladder Carcinoma | Phase 2 | Withdrawn | Case Comprehensive Cancer Center | 2026-09-01 | 2026-09-24 | |
| The Combined Role of FAPI PET and Liquid Biopsy in the Staging and Clinical Management of Bladder Cancer - FUTURE Trial FAPI PET/CT and liquid biopsy in patients eligible for radical cystectomy, FAPI PET/CT and liquid biopsy in patients eligible for conservative treatment - Bladder Cancer | Phase 2 | Not yet recruiting | Chiti Arturo | 262 | 2026-09-01 | 2025-12-02 |
| A Study of Radiation Therapy and Cemiplimab With or Without Fianlimab In People With Bladder Cancer Stereotactic body radiotherapy, Cemiplimab, Cemiplimab and Fianlimab - Bladder Urothelial Carcinoma | Phase 2 | Withdrawn | Memorial Sloan Kettering Cancer Center | 2026-09-01 | 2026-09-03 | |
| Enfortumab Vedotin + Pembrolizumab Induction to Spare the Bladder in MIBC Enfortumab Vedotin, Pembrolizumab, Radiation - Urothelial Bladder Cancer | Phase 2 | Not yet recruiting | The Netherlands Cancer Institute | 56 | 2026-09-01 | 2026-06-25 |
| Consolidative Therapy After EV + Pembrolizumab in Muscle Invasive Bladder Cancer, REINFORCE Trial Intensity-Modulated Radiation Therapy, Volume Modulated Arc Therapy, Radiosensitizing Agent - Muscle Invasive Bladder Carcinoma, Stage III Bladder Cancer AJCC v8 | Phase 1 / Phase 2 | Recruiting | University of Washington | 12 | 2026-08-20 | 2026-08-25 |
| Role of NAC in cT0 Muscle-invasive Bladder Cancer After Maximal TURBt cisplatin based neoadjuvant chemotherapy, Radical cystectomy alone - Muscle-Invasive Bladder Carcinoma, Chemotherapy Effect | Phase 3 | Active not recruiting | Regina Elena Cancer Institute | 236 | 2026-08-13 | 2026-08-17 |
| Neoadjuvant RC48 Plus Gemcitabine in HER2-Expressing MIBC Gemcitabine, Toripalimab, Disitamab Vedotin (RC48) - MIBC | Phase 3 | Recruiting | Zhiquan Hu | 170 | 2026-07-01 | 2026-07-09 |
| Radical CystEctomy or RaDio-chEMotherapy as Preferred Treatment for invasivE blaDder Cancer Radiochemotherapy, Radical cystectomy - Muscle Invasive Bladder Cancer | Not applicable | Not yet recruiting | Brazilian Clinical Research Institute | 336 | 2026-06-01 | 2026-02-12 |
| Consolidative Local Therapy (CLT) in Oligo-metastatic Urothelial Carcinoma Radical cystectomy - Locally Advanced Urothelial Carcinoma, Oligo-metastaic Urothelial Carcinoma | Phase 2 | Recruiting | Yale University | 32 | 2025-11-26 | 2026-10-07 |
| Ablative Technique For Ovarian Preservation In Endometrioma Cystectomy, plasma vaporization, Sclerotherapy - Endometrioma, Fertility | Not applicable | Recruiting | Clinique Tivoli Ducos | 332 | 2025-09-18 | 2026-03-19 |
| Effect of Neoadjuvant Chemotherapy on MRI Accuracy Before Cystectomy Neoadjuvant Chemotherapy, Radical Cystectomy - Muscle Invasive Bladder Cancer | Not applicable | Recruiting | Assiut University | 76 | 2025-09-01 | 2025-10-02 |
| Disitamab Vedotin Combined With Ivonescimab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer Disitamab Vedotin Injection, Ivonescimab（AK112，a PD-1/VEGF bispecific antibody）, Radical Cystectomy with Pelvic Lymph Node Dissection - Bladder Cancer, Muscle-invasive Bladder Cancer | Phase 1 / Phase 2 | Not yet recruiting | Sun Yat-sen University | 30 | 2025-04-30 | 2025-05-04 |
| Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial Biospecimen Collection, Computed Tomography, Cystectomy - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis and Ureter Urothelial Carcinoma | Phase 4 | Recruiting | Mayo Clinic | 75 | 2025-01-08 | 2026-10-01 |
| Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy Biospecimen Collection, Computed Tomography, Durvalumab - Bladder Urothelial Carcinoma, Muscle Invasive Bladder Carcinoma | Phase 2 | Recruiting | Yuanquan Yang | 24 | 2024-12-30 | 2026-10-01 |
| Assessment of Decision Tool to Select Women for Gynecologic Sparing Radical Cystectomy Reproductive organ sparing radical cystectomy, Radical cystectomy - Urothelial Carcinoma Bladder | Phase 2 | Recruiting | University of Florida | 127 | 2024-08-30 | 2026-09-09 |
| RC48 Combined With Toripalimab as Neoadjuvant Therapy for Cisplatin Ineligible MIBC Patients DisitamabVedotinForIicction Toripalimab - Bladder Cancer, Muscle-Invasive Bladder Carcinoma | Phase 1 / Phase 2 | Recruiting | Zhujiang Hospital | 55 | 2024-06-19 | 2026-10-08 |
| Neoadjuvant Adebrelimab Plus Etoposide and Cisplatin in Neuroendocrine Bladder Carcinoma Adebrelimab, Etoposide, Cisplatin - Neuroendocrine Carcinoma of the Bladder, Bladder Cancer | Phase 2 | Recruiting | RenJi Hospital | 22 | 2023-11-16 | 2025-12-08 |
Showing 20 of 70. Sign in to see all of them.
Urinary Bladder Neoplasms (47) · Carcinoma, Transitional Cell (4) · Endometriosis (4) · Carcinoma, Renal Cell (2) · Urinary Bladder Diseases (2) · Urologic Diseases (2) · Adrenal Gland Neoplasms (1) · Bacterial Infections (1) · Cone Dystrophy 3 (1) · Cross Infection (1) · Delirium (1) · Disease Progression (1) · Hernia (1) · Ileus (1) · Infections (1)
University of Washington (5) · Assiut University (3) · Memorial Sloan Kettering Cancer Center (3) · University of Southern California (3) · Mayo Clinic (2) · Merck Sharp & Dohme LLC (2) · Radiation Therapy Oncology Group (2) · UNC Lineberger Comprehensive Cancer Center (2) · Ain Shams University (1) · Alliance for Clinical Trials in Oncology (1) · AstraZeneca (1) · Brazilian Clinical Research Institute (1) · Bristol-Myers Squibb (1) · CAMC Health System (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1)
United States (36) · China (8) · France (8) · Italy (8) · Germany (7) · Canada (5) · Poland (5) · Spain (5) · United Kingdom (5) · Belgium (4) · Denmark (4) · Israel (4) · Mexico (4) · Turkey (Türkiye) (4) · Argentina (3)
Noah Hahn, M.D. (2) · Petros Grivas (2) · Abai Xu, doctor (1) · Ahmed Lotfy Ghazy, Lecturer of Urology (1) · Alexander Kutikov, MD (1) · Amr Darwish, Lecturer (1) · Anthony L. Zietman, MD (1) · Arcangelo Sebastianelli, MD (1) · Brian Costello (1) · Charlene Mantia, MD (1) · Cheryl T. Lee, MD (1)
PMID 34008425, PMID 10470696, PMID 11157016, PMID 11748987, PMID 11923603, PMID 12118019, PMID 12136861, PMID 12944571, PMID 15273542, PMID 15814643, PMID 16518661, PMID 17077107, PMID 17116130, PMID 18295861, PMID 18456668, PMID 18803341, PMID 19222048, PMID 19826360, PMID 20089114, PMID 21205754, PMID 21502557, PMID 23228446, PMID 23706253, PMID 23823157, PMID 24613684, PMID 25366678, PMID 25392649, PMID 25840895, PMID 26291459, PMID 26293795, PMID 26433570, PMID 26579498, PMID 27001593, PMID 27123543, PMID 27194259, PMID 27649314, PMID 29281848, PMID 30280456, PMID 30763236, PMID 31900121, PMID 32360052, PMID 33109737, PMID 33430820, PMID 33617327, PMID 34856936, PMID 35703113, PMID 36639814, PMID 38865671, PMID 39928165, PMID 40329651
2018 (3), P30CA014089 (3), 2016 (1), 2023 (1), P30CA015083 (1), P30CA015704 (1), P30CA016086 (1), U10CA180821 (1), UL1TR001120 (1)